Gilead Sciences Exec Says Raising Full Year HIV Growth Expectations To 9%-10% YoY From Prior Guidance Of 8% Growth; Launch Preparations Fully Underway For Anito-Cel Cell Therapy, With Five Months To Go Until FDA PDUFA Date; Do Not Currently Anticipate Pursuing Additional Sizable M&A Transactions This Year
-Conference Call
Share
Why It Matters
Gilead raised its HIV medicine growth forecast to 9%-10% per year, showing their current drugs are selling better than expected. This tells you the company is doing well with what it already has, so watch whether they keep hitting these higher goals.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.